Ahmad Masri is the Director of the HCM Center and Assistant Professor of Medicine at Oregon Health & Science University in Portland, Oregon. His research focuses on improving early recognition of hypertrophic cardiomyopathy and transforming HCM into a medically treatable disease. Dr. Masri and his team have been heavily involved in numerous randomized clinical trials in the Hypertrophic Cardiomyopathy space, most recently as the lead Co-PI on the REDWOOD-HCM OLE trial.
Andrew Wang, MD is a Professor of Medicine at Duke University Health System in Durham, NC and serves as the Vice Chief for Cardiology. He received his medical degree at Duke, internal medical residency training at the Johns Hopkins Hospital, and cardiology fellowship training at Duke. His clinical and research interests are focused on hypertrophic cardiomyopathy (HCM) and structural heart diseases. Since 2003, he has directed the Duke HCM clinic, part of the Adult Cardiovascular Genetics Clinic and an HCMA Center of Excellence. He has been actively involved in clinical trials and registries in HCM, including serving on steering committees for recent and ongoing trials.
Dr. Anjali Tiku Owens is the Founding Director of the Center for Inherited Cardiovascular Disease and Director of the Familial Cardiomyopathy Program at the University of Pennsylvania Perelman School of Medicine. She is an Assistant Professor of Medicine in the Division of Cardiology, Section of Heart Failure, Transplantation and Mechanical Circulatory Support. Dr. Owens completed undergraduate education and medical school at Duke University before completing residency, Chief Residency and fellowship at the University of Pennsylvania. Dr. Owens has a special interest in genetic forms of cardiomyopathy and emerging novel therapeutics.
Dr. Carolyn Yung Ho is the medical director of the Cardiovascular Genetics Center at Brigham and Women’s Hospital (BWH). A cardiovascular medicine specialist, she is also an associate professor of medicine at Harvard Medical School (HMS).
She received her medical degree from HMS. She then completed an internal medicine residency and a cardiology fellowship at BWH. Dr. Ho is board certified in internal medicine and cardiovascular disease.
Dr. Ho’s clinical interests include cardiomyopathy, echocardiography, and cardiovascular genetics. The author of over 30 peer-reviewed publications, her research focuses on characterizing early phenotypes of sarcomere mutations in inherited cardiomyopathies and developing clinical trials to diminish the progression of hypertrophic cardiomyopathy. Her research has received support from the American College of Cardiology and National Institutes of Health.
Heidi Salisbury, RN, MSN, CNS-BC, ACGN joined Stanford Health Care as a bedside nurse in the coronary care unit in 2001. In 2006, she co-founded the Stanford Center for Inherited Cardiovascular Disease (SCICD) and is the Program Operations Coordinator. As a Clinical Nurse Specialist, board-certified in genetics, Heidi is dedicated to mentoring nurses, genetic counselors, and physician fellows to develop the clinical skills and gain the knowledge base necessary to expertly manage patients with inherited heart disease. Heidi is passionate about training the next generation of providers to think genetically when approaching the care of this population. Heidi advocates for building programmatic infrastructure that supports a continuum of expert-level nursing care through the individual lifespan and across the generations of a family. Heidi has a background in exercise physiology and cardiac rehabilitation from Cal Poly, San Luis Obispo. She completed graduate and post-graduate work in cardiovascular nursing science at San Francisco State/UCSF. Heidi is active in leadership roles with the American Heart Association, the International Society of Nursing and Genomics, the Preventative Care Nursing Association and Stanford Health Care’s APP Institute. She enjoys spending time with her family and friends, exploring the outdoors, coaching youth soccer, practicing yoga, anything dark chocolate, and trying new things.
Prof. Iacopo Olivotto is Head of the Cardiomyopathy Unit and Associate Professor of Cardiovascular Medicine at Careggi University Hospital in Florence, Italy. Over the last two decades, his main clinical and research interests have includes various aspects of cardiomyopathies, with special focus on hypertrophic cardiomyopathy. Prof. Olivotto has been involved in the design and execution of randomized studies in genetic cardiomyopathies, and has served as the lead investigator of the recently presented Explorer HCM trial. He has co-authored over 250 papers in international, peer-reviewed journals.
A/Prof Jodie Ingles is Head of the Clinical Genomics Laboratory at Centre for Population Genomics, The Garvan Institute of Medical Research and Murdoch Children’s Research Institute. She is a cardiac genetic counsellor in the Department of Cardiology, Royal Prince Alfred Hospital with more than 18 years' experience working with families with inherited heart diseases. She is an NHMRC Career Development Fellow, and received an NHMRC Excellence Award for the top ranked application in 2018.
Juan Pablo Kaski
Dr Kaski is Associate Professor of Paediatric Inherited Cardiology at the UCL Institute of Cardiovascular Science, where he leads the UCL Centre for Paediatric Inherited and Rare Cardiovascular Diseases, and Consultant Paediatric Cardiologist at Great Ormond Street Hospital (GOSH), London, UK. He is the Director of the GOSH Centre for Inherited Cardiovascular Diseases, the largest centre in Europe dedicated to the investigation and management of inherited cardiac conditions in childhood. Dr Kaski’s clinical and research interests are focused on the clinical and genetic characterisation of inherited cardiovascular disease and sudden cardiac death in childhood and he won the Young Investigator Award for Clinical Science from the European Society of Cardiology in 2008 for his work on the genetic basis of pre-adolescent hypertrophic cardiomyopathy. He leads an international paediatric HCM consortium of over 45 centres, which was responsible for the development of the first sudden death risk prediction model for childhood HCM.
The Hypertrophic Cardiomyopathy Association is not just a cause or a hobby for Lisa Salberg, Founder and CEO of HCMA. Lisa was diagnosed with HCM at age 12 after a murmur was detected at a school physical. Three weeks after her wedding, at the age of 21, Lisa suffered a stroke secondary to HCM. In 1997, she received her first ICD (implantable cardiac defibrillator), the only true protection against sudden cardiac arrest. She also takes an assortment of cardiac medications to control her HCM. In 2016 it was clear her heart was failing and transplant was the only option left. She was placed on an IV medication via a PICC line and lived with this medication from September to February 2, 2017 when the call came at 12:23am Groundhogs Day that a heart had been located. The surgery was completed by 5pm and she woke up to a new life at 8:05am February 3, 2017 and was up walking within 24 hours. Since Lisa founded HCMA in 1996 as a national resource and support center for families affected by HCM. The HCMA has an active membership of over 7,800 families with HCM and provides information to the world via its website which serves an estimate 300,000 people per year.
Dr. Martin Maron is Director of the Hypertrophic Cardiomyopathy Center and Research Institute at Tufts Medical Center and the Chanin T. Mast Hypertrophic Cardiomyopathy Center in Morristown Medical Center. His research interests are the diagnosis and management of hypertrophic cardiomyopathy including the role of cardiovascular magnetic resonance in assessment of patients with HCM and novel drug therapy to modify the disease. Dr. Maron has co-authored over 200 original publications on HCM including in New England Journal of Medicine, Lancet, Circulation and Journal of the American College of Cardiology.
Dr. Matthew Martinez is Associate Professor of Medicine. He serves as Co-Director of Hypertrophic Cardiomyopathy program and Director of Sports Cardiology at Morristown Medical Center, Atlantic Health System in New Jersey. Dr. Martinez serves as a cardiology consultant for elite and professional athletes including acting as the League cardiologist for Major League Soccer, team cardiologist for the New York Jets and cardiac consultant for the NFL. He regularly presents on Sports Cardiology and Hypertrophic cardiomyopathy at national and international meetings and served as the American College of Cardiology’s Chair of Sports and Exercise section until 2020. He has expertise in advanced cardiac imaging using echo, cardiac MRI and CT and has led many educational events nationally and internationally on these topics.
Milind Desai, MD MBA, is the Director of Clinical Operations of the Robert and Suzanne Tomsich Department of Cardiovascular Medicine at the Sydell and Arnold Miller Family Heart, Vascular & Thoracic Institute at Cleveland Clinic. He is a Professor of Medicine at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. He holds the Haslam Family Endowed Chair in Cardiovascular Medicine. He has dual appointments in the Departments of Cardiovascular Medicine (Section of Cardiovascular Imaging) and Radiology.
Dr. Desai is the Director of Center for Hypertrophic Cardiomyopathy, the Medical Director of the Center for Aortic Diseases, the Medical Director for Center for Radiation Heart Disease and an integral part of the Center for Valvular heart disease. He is an expert in multimodality cardiovascular imaging, having achieved the highest level of proficiency in all imaging modalities, including cardiac MRI, cardiac CT, echocardiography and nuclear cardiology. In addition, he serves on the multiple Heart, Vascular & Thoracic Institute councils, including Executive Council, Operations Council and Research Council. In addition, he serves on the Cleveland Clinic Research Compliance Committee.
Nicholas G. Smedira, MD, MBA is a staff cardiothoracic surgeon in the Department of Thoracic and Cardiovascular Surgery and former Director of Quality for the Sydell and Arnold Miller Family Heart, Vascular & Thoracic Institute at Cleveland Clinic. He is board-certified in thoracic surgery.
As principal or co-investigator in more than 100 clinical trials and studies, Dr. Smedira has focused his research efforts on his specialty interests, including the surgical treatment of patients with ischemic heart failure, cellular therapy for advanced heart damage, the use of bivalirudin as an alternative to heparin during cardiac surgery, and rotary blood pumps, such as the HeartWare and HeartMate II devices, which are used to support patients until they receive a transplant (bridge-to-transplant) or for permanent cardiac support (destination therapy).
In 2008, Dr. Smedira became Director of Quality for the Miller Family Heart, Vascular & Thoracic Institute and in this role, he guides the efforts to improve the quality and safety of healthcare at Cleveland Clinic. Dr. Smedira’s quality-related committee memberships include the Quality Institute Executive Team, the Quality and Patient Safety Committee of the Board of Directors, and is the Chairman of the Professional Conduct Committee.
Sara Saberi, M.D., M.S. is an Assistant Clinical Professor in the Division of Cardiovascular Medicine and a Co-Director of the Inherited Cardiomyopathy Program at University of Michigan. She received her bachelor's degree from Northwestern University in Evanston, IL and her medical degree from Wayne State University in Detroit, MI. She obtained her residency training in Internal Medicine and fellowship training in Cardiovascular Medicine at University of Michigan. She joined the faculty at Michigan in 2010. Dr. Saberi’s clinical work is focused on providing comprehensive care to patients with genetic cardiomyopathies and their families. Her research work focuses on clinical research aimed at understanding environmental factors that impact disease onset and progression in hypertrophic cardiomyopathy. She is also involved in clinical trials of new treatments to prevent or delay onset and progression of the disease. One of her areas of focus is determining the impact of exercise training on clinical outcomes, disease features, and quality of life in patients with hypertrophic cardiomyopathy and establishing evidence-based guidelines to inform recommendations for athletes with cardiomyopathies.
Dr. Srihari S. Naidu is Director of the Hypertrophic Cardiomyopathy Center of Excellence and Cardiac Catheterization Laboratory at Westchester Medical Center in New York, and Professor of Medicine at New York Medical College. A comprehensive HCM program certified by the HCM Association, his center has particular expertise in alcohol septal ablation, performing the most annually in the United States, while also offering surgical myectomy, heart transplantation and the full gamut of services, following currently 1500 patients actively. He is Editor of Hypertrophic Cardiomyopathy, the main HCM Textbook by Springer, now in Second Edition, and speaks regularly at the American Heart Association and American College of Cardiology annual meetings. He a 2 term Trustee of the Society for Cardiovascular Angiography and Interventions (SCAI) and President of the NY Chapter of the American College of Cardiology. He has published over 200 original manuscripts, review articles, and book chapters, and is on the advisory board for Bristol Myers Squibb and Cytokinetics. Dr. Naidu is a Trustee Emeritus of Brown University.
Steve R. Ommen, M.D., is a board-certified cardiologist with special interest in hypertrophic cardiomyopathy (HCM) and valvular heart disease. His undergraduate degree is in biomedical engineering from Northwestern University in Evanston, Illinois. He graduated from Mayo Medical School (now Mayo Clinic School of Medicine) and obtained specialty training in internal medicine and cardiology at Mayo Clinic in Rochester, Minnesota.
Dr. Ommen is the Medical Director of the Mayo Hypertrophic Cardiomyopathy Clinic, the largest and longest continuous single center specializing in HCM and has been actively engaged in clinical research for patients with HCM for over two decades. He also has led national practice guidelines for HCM. He has been honored with awards for clinical care, individual excellence, and team excellence.
Theodore Abraham, MD. FACC is the Meyer Friedman Distinguished Professor of Medicine and co-Director of the HCM Center of Excellence at University of California, San Francisco (UCSF). He has approximately 20 years of experience in the diagnosis and treatment of HCM. His particular clinical and research interests are in the field of Echocardiography and cardiac imaging as it relates to HCM. His research focus is cardiac mechanics spanning translational models and clinical imaging. He is a site investigator for several HCM-related drug trials including but not limited to EXPLORER-HCM and REDWOOD-HCM. He has over 150 peer-reviewed publications and has been NIH-funded as principal or co-investigator continuously for the last 20 years. He served on the Board of Directors for the American Society of Echocardiography and was the Program Chair for the ASE 2020 Scientific Sessions. He has served or serves on the editorial boards of the JACC, JACC Cardiovascular Imaging, JASE and Circulation Imaging.
Hugh Watkins is the Radcliffe Professor of Medicine at the University of Oxford and Honorary Consultant in Cardiology at the John Radcliffe Hospital. He is lead investigator of CureHeart, a programme aiming to create genetic therapy cures for cardiomyopathy, funded by the BHF Big Beat Challenge.
Professor Watkins has contributed to the understanding of the molecular genetic basis of cardiovascular disease, using genetic approaches to define disease mechanisms and to improve diagnosis and treatment of patients and families with inherited diseases. Through both his Mendelian and complex trait genetics work, Professor Watkins has defined some of the most medically important disease genes affecting the cardiovascular system. He has built up a specialist clinical and laboratory genetic service in Inherited Cardiac Conditions in Oxford.
He is a Fellow of the Royal Society and a Fellow of the Academy of Medical Sciences.